1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Επιστημών Υγείας
  4. Τμήμα Ιατρικής
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/19965
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSkarlos, P.en
dc.contributor.authorChristodoulou, C.en
dc.contributor.authorKalogeras, K. T.en
dc.contributor.authorEleftheraki, A. G.en
dc.contributor.authorBobos, M.en
dc.contributor.authorBatistatou, A.en
dc.contributor.authorValavanis, C.en
dc.contributor.authorTzaida, O.en
dc.contributor.authorTimotheadou, E.en
dc.contributor.authorKronenwett, R.en
dc.contributor.authorWirtz, R. M.en
dc.contributor.authorKostopoulos, I.en
dc.contributor.authorTelevantou, D.en
dc.contributor.authorKoutselini, E.en
dc.contributor.authorPapaspirou, I.en
dc.contributor.authorPapadimitriou, C. A.en
dc.contributor.authorPectasides, D.en
dc.contributor.authorGogas, H.en
dc.contributor.authorAravantinos, G.en
dc.contributor.authorPavlidis, N.en
dc.contributor.authorArapantoni, P.en
dc.contributor.authorSkarlos, D. V.en
dc.contributor.authorFountzilas, G.en
dc.date.accessioned2015-11-24T19:04:04Z-
dc.date.available2015-11-24T19:04:04Z-
dc.identifier.issn1432-0843-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/19965-
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntineoplastic Combined Chemotherapy Protocols/therapeutic useen
dc.subjectBreast Neoplasms/*drug therapy/genetics/metabolismen
dc.subjectChemotherapy, Adjuvanten
dc.subjectClinical Trials, Phase III as Topicen
dc.subjectCluster Analysisen
dc.subjectDisease-Free Survivalen
dc.subjectDose-Response Relationship, Drugen
dc.subjectEstrogen Receptor alpha/genetics/metabolismen
dc.subjectEstrogen Receptor beta/genetics/metabolismen
dc.subjectFemaleen
dc.subjectGene Expression Regulation, Neoplasticen
dc.subjectHumansen
dc.subjectImmunohistochemistryen
dc.subjectMiddle Ageden
dc.subjectOutcome Assessment (Health Care)/methodsen
dc.subjectPhenotypeen
dc.subjectPrognosisen
dc.subjectRandomized Controlled Trials as Topicen
dc.subjectReceptor, erbB-2/genetics/*metabolismen
dc.subjectReceptors, Estrogen/genetics/*metabolismen
dc.subjectReceptors, Progesterone/genetics/*metabolismen
dc.subjectReverse Transcriptase Polymerase Chain Reactionen
dc.subjectTranslational Medical Research/methodsen
dc.subjectYoung Adulten
dc.titleTriple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trialen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primary10.1007/s00280-011-1730-9-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/21901395-
heal.identifier.secondaryhttp://www.springerlink.com/content/67838739r664lh67/fulltext.pdf-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2012-
heal.abstractPURPOSE: It is well recognized that breast cancer is a heterogeneous disease. The purpose of the current study was to classify patients according to the immunohistochemical phenotype of their tumors in an effort to evaluate the outcome of the respective groups of patients and specifically of those with triple-negative breast cancer (TNBC) following dose-dense sequential adjuvant chemotherapy. METHODS: A total of 595 patients with high-risk breast cancer were treated with adjuvant anthracycline-based dose-dense sequential chemotherapy with or without paclitaxel in the context of a randomized study. ER, PgR, HER2, Ki67, EGFR, and CK5 protein expression were evaluated in 298 formalin-fixed paraffin-embedded tumor samples by immunohistochemistry (IHC). HER2 was also evaluated by chromogen in situ hybridization (CISH). HER2 status and Ki67 protein expression differentiated luminal IHC subtypes (luminal B tumors being HER2 and/or Ki67-positive). RESULTS: Among the 298 tumors, the immunohistochemical panel classified 37 (12%) as luminal A, 198 (66%) as luminal B, 27 (9%) as HER2 enriched, and 36 (12%) as TNBC. The median follow-up time was 97 months. Patients with luminal A tumors had the best prognosis, with improved disease-free survival (log-rank, P = 0.033) and overall survival (P = 0.006) compared with the other three tumor subtypes. The three subtypes had an increased risk for relapse and death compared with luminal A in multivariate analysis, as well. No benefit from paclitaxel treatment was detected in any of the four subtypes or the total cohort. Hierarchical clustering based on mRNA expression of ER, PgR, and HER2 by quantitative RT-PCR identified patient groups that were comparable to the subtypes identified by IHC. CONCLUSIONS: The results of this study confirm that triple negative, luminal B and HER2-enriched phenotypes identified by IHC are of adverse prognostic value in high-risk breast cancer patients treated with dose-dense sequential adjuvant chemotherapy.en
heal.journalNameCancer Chemother Pharmacolen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Show simple item record
Files in This Item:
File Description SizeFormat 
Skarlos-2012-Triple-negative phen.pdf992.08 kBAdobe PDFView/Open    Request a copy
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons